Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX and Radiotherapy in Gastroesophageal Junction Adenocarcinoma
NCT01962246Phase 3Completed
- Sponsor
- Hebei Medical University
- Start
- Feb 2012
- Primary completion
- Feb 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in gastroesophageal junction adenocarcinoma, sponsored by Hebei Medical University. Primary endpoint: Disease-Free Survival at 3 years. Started Feb 2012; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01962246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962246.